-
Mashup Score: 2Antitumor T cell responses detected in patients with new vaccine strategy in immune-cold tumors - 4 month(s) ago
Pant et al. described the AMPLIFY-201 phase 1 trial assessing the vaccine ELI-002 2P in patients with colorectal cancer and pancreatic ductal adenocarcinoma. Patients had received locoregional treatment and had minimal residual disease. The vaccine was found to be safe and well tolerated. A decline in circulating tumor DNA (ctDNA) and/or serum tumor antigen levels (CEA and CA19-9) was observed in 84% of patients, and complete clearance of ctDNA was observed in 24% of patients. Polyfunctional responses were detected in both CD4+ and CD8+ T cells, and T cell responses to various mutated KRAS antigens, including the two included in the vaccine, were induced. T cell responses correlated with tumor biomarker clearance.
Source: acir.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1GLOBAL SUMMIT ON GASTROINTESTINAL MALIGNANCIES - 7 month(s) ago
OCTOBER 4 – OCTOBER 8, 2023 FAIRMONT HAMILTON PRINCESS, HAMILTON, BERMUDA Once you’ve signed up below – you will receive a calendar invite to your registered email address! If you have any questions, please reach out to us at omiops@davaonc.com.
Source: docs.google.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DAVAOnc: All practicing HCPs are welcome to tune in virtually! (Registration Link: https://t.co/5nMS4G0iFW) Grab a cup of coffee and co…
-
-
Mashup Score: 1
Anirban Maitra and Shubham Pant from MD Anderson tell us what targets and approaches look promising in pancreatic cancer.
Source: BiotechTVCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @BiotechTVHQ: The latest trends in pancreatic cancer research with two experts from MD Anderson. #ASCO23 https://t.co/Nn6lw5WYGA
-
-
Mashup Score: 4Program Guide – ASCO Meeting Program Guide - 11 month(s) ago
AuthorsEileen Mary O’ReillyMemorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NYEileen Mary O’Reilly, Zev A. Wainberg, Colin D. Weekes, Muhammad Furqan, Pashtoon Murtaza Kasi, Craig E. Devoe, Alexis Diane Leal, Vincent Chung, James Perry, Lochana Seenappa, Lisa McNeil, Esther Welkowsky, Peter DeMuth, Christopher M. Haqq, Shubham PantOrganizationsMemorial Sloan…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
🤩🤩 to be a collaborator and senior author on this important trial testing a #KRAS vaccine in patients to prevent recurrence. Presented by amazing collaborator and colleague @EileenMOReilly @MDAndersonNews @MSKCancerCenter @OncoAlert @ASCO @Aiims1742 https://t.co/8kgZDjU7bv https://t.co/QvDB7uMY11
-
-
Mashup Score: 0Pancreatic cancer rates rising in young women, study says - 1 year(s) ago
Maria Menounos revealed that she recently survived pancreatic cancer. Pancreatic cancer rates are rising in young women.
Source: FOX 26 HoustonCategories: Hem/Oncs, Latest HeadlinesTweet-
Thank you 🙏 🙏 @FOX26Houston for helping spread awareness about #PancreaticCancer #Endcancer @MDAndersonNews @LanyKimmons @letswinpc @PanCAN @Aiims1742 https://t.co/vYI7gdMecc
-
-
Mashup Score: 3Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial - PubMed - 1 year(s) ago
Patients with rare solid tumors treated on early phase trials experience toxicities from their tumors and treatments. However, limited data exist to describe the detailed symptom burden suffered by these patients, particularly those with rare solid tumors treated with immunotherapy. We performed a p …
Source: PubMedCategories: Latest Headlines, Oncologists1Tweet-
RT @LabNaing: PRO in pts with rare cancers receiving pembrolizumab in a phase II Clinical Trial: https://t.co/8rGsyBVHhh by @DavidHongMD @B…
-
-
Mashup Score: 0ASCO Plenary Series Program - 1 year(s) ago
Learn more about the faculty and program for the April Plenary Series session.
Source: ASCOCategories: Hem/Oncs, Latest HeadlinesTweet-
📢📢 On Behalf of my Co-Investigators 🤩🤩 to present ➡️Adargrasib (#KRAS G12C inhibitor) in solid tumors with #KRAS G12C mutation. 🙏🙏 @ASCO for the platform. ⏰ Join us Virtually 4/20 @3 PM EST ⏰ Presentation ➕ Q&A ➡️ Details https://t.co/JEXcePm5Rt https://t.co/LhVKTVDlKr
-
-
Mashup Score: 0
Erdafitinib is an oral selective pan-FGFR tyrosine kinase inhibitor which is approved to treat patients with locally advanced or metastatic…
Source: VJOncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Discussing results of the #Cholangiocarcinoma cohort with #FGFR alterations 💊 with #Erdafitinib. Results presented @asco #GI23 @VJOncology @curecc https://t.co/DfLZa48a33
-
-
Mashup Score: 1
Patients with cholangiocarcinoma harboring FGFR alterations (FGFRalt) who were treated with open-label erdafitinib had an objective response rate by independent review of 60%, with a median time to onset of response of 1.5 months (Abstract 610).
Source: ASCO Daily NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
🚨🚨#Erdafitinib 🎯in patients with #cholangiocarcinoma and #FGFR alterations @ASCO #GI23 ➡️ ORR 60% ➡️ DCR 100% ➡️ Median PFS 8.4 months 🙏🙏 Patients, caregivers, co-investigators, advocates https://t.co/Ahlm54Lxoi
-
-
Mashup Score: 0Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab | Zymeworks Inc. - 1 year(s) ago
Zanidatamab as monotherapy produced a confirmed objective response rate (cORR) of 41.3% and median duration of response of 12.9 months in patients with previously treated HER2-amplified and expressing biliary tract cancers (BTC) Pending receipt of regulatory approvals, zanidatamab has the potential
Source: Zymeworks Inc.Categories: Hem/Oncs, Latest HeadlinesTweet-
🙏 for mentorship @JavleMilind @GIcancerDoc #BiliaryTractCancers #Her2Neu #PrecisionMedicine @curecc @CCA_Alliance @CholangioNet @OncoAlert @AHPBA @ravimehro @SirohiBhawna @rachnatshroff @MiteshBorad @FlavioRochaMD @VivekSubbiah @pashtoonkasi @drlauragoff https://t.co/dpAcbdPaOA
-
RT @ACIR_org: Results of a vaccine phase 1 trial in colorectal and pancreatic cancer. Read our summary here: https://t.co/4HFVWg6A7x @MDAn…